Washington, D.C. - A PETA International Science Consortium advisor, Joseph Manuppello, will present the "Animal Protection Perspective" at a workshop sponsored by the U.S. Food and Drug Administration (FDA) intended to identify in vitro models and assays for tobacco toxicity testing.
The workshop, Assessment of In Vitro COPD [Chronic Obstructive Pulmonary Disease] Models for Tobacco Regulatory Science, was designed by the nonprofit laboratory, the Institute for In Vitro Sciences (IIVS), to bring together experts and participants to specifically address the relevant research goals of the FDA's Center for Tobacco Products.
According to IIVS, the research priorities of the Center for Tobacco Products include the identification of in vitro models and assays for assessing tobacco constituent or compound hazards and for comparing the respiratory toxicity of different tobacco products.
Areas to be explored in the workshop include:
- Inflammation and Oxidative Stress
- Ciliary Dysfunction and Ion Transport
- Goblet Cell Hyperplasia and Mucus Production
- Parenchymal/Bronchial Tissue Destruction and Remodeling
The introductory session will feature speakers from the FDA's Center for Tobacco Products, tobacco manufacturer R. J. Reynolds, and the PETA International Science Consortium presenting regulatory, industry, and animal protection perspectives.
Manuppello will discuss opportunities for minimizing animal use within the current regulatory environment for tobacco products. "Tobacco products can and must be tested using nonanimal testing methods as the standard, and the FDA must exercise its authority to avoid harming animals," says Manuppello.
The workshop in Bethesda, Maryland will be held December 8-10 at North Bethesda Marriott and Conference Center, 5701 Marinelli Road. For more information about nonanimal testing methods, please visit the PETA International Science Consortium, Ltd., website.